Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
  • A01N43/72—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
  • A01N43/82—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with three ring hetero atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D231/16—Halogen atoms or nitro radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
  • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
  • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/38—Nitrogen atoms
  • C07D277/40—Unsubstituted amino or imino radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D277/38—Nitrogen atoms
  • C07D277/44—Acylated amino or imino radicals
  • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

• the present invention relates to 3-[(1 ,3-thiazol-4-ylmethoxyimino)(phenyl)methyl]-2-substituted-1 ,2,4- oxadiazol-5(2H)-one derivatives, their process of preparation, their use as fungicide active agents, particularly in the form of fungicide compositions, and methods for the control of phytopathogenic fungi, notably of plants, using these compounds or compositions.
• T , L1 a methylene linker and A an heterocycle.
• the present invention provides 3-[(1 ,3-thiazol-4-ylmethoxyimino)(phenyl)methyl]-2- substituted-1 ,2,4-oxadiazol-5(2H)-one derivatives of formula (I)
• X 1 represents a substituted or non-substituted CrC 8 -alkyl, substituted or non-substituted C 3 -C 8 - cycloalkyl, substituted or non-substituted C2-C 8 -alkenyl, substituted or non-substituted C2-C 8 -alkynyl, substituted or non-substituted CrC 8 -alkylcarbonyl;
• - Z 1 represents a hydrogen atom, a halogen atom, a nitro group, an amino group, an hydroxyamino group, a cyano group, a carboxylic acid group, substituted or non-substituted Ci -C 8 -alkoxyamino group, substituted or non-substituted Ci -C 8 -alkylamino, substituted or non-substituted C 3 -Ci 0 - cycloalkylamino, substituted or non-substituted C 3 -Ci 0 -cycloalkenylamino, substituted or non- substituted C3-Cio-cycloalkyl-Ci -C 8 -alkylamino, substituted or non-substituted aryl-CrC 8 -alkylamino, substituted or non-substituted Ci -C 8 -alkoxy-Ci -C 8 -alkylamino, substitute
• - Q represents a hydrogen atom, substituted or non-substituted CrC 8 -alkyl, substituted or non-substituted C 3 -C 8 -cycloalkyl, a substituted or non-substituted C 2 -C 8 -alkenyl, substituted or non-substituted C3-C 8 -cycloalkenyl, substituted or non-substituted C2-C 8 -alkynyl, substituted or non-substituted CrC 8 -alkoxy, substituted or non-substituted C 2 -C 8 -alkenyloxy, substituted or non-substituted C2-C 8 -alkynyloxy, substituted or non-substituted Ci -C 8 -alkylamino, substituted or non-substituted C rC 8 -alkylsulfenyl, substituted or non-substituted C 2 -
• - U represents a oxygen atom or a sulfur atom
• R a represents a hydrogen atom, a hydroxy group, substituted or non-substituted CrC 8 -alkyl, substituted or non-substituted C 3 -C 8 -cycloalkyl, a substituted or non-substituted C 2 -C 8 -alkenyl, substituted or non-substituted C 2 -C 8 -alkynyl, substituted or non-substituted CrC 8 -alkoxy, substituted or non-substituted C 3 -Ci 0 -cycloalkenyl, substituted or non-substituted C 5 -Ci 2 -fused bicycloalkyl, substituted or non-substituted Cs-Ci 2 -fused bicycloalkenyl, substituted or non- substituted aryl, or substituted or non-substituted heterocyclyl, substituted or non-substituted CrC 8 -al
• - Z 2 represents a hydrogen atom, a halogen atom, substituted or non-substituted Ci -C 8 -alkyl, substituted or non-substituted C 3 -C 8 -cycloalkyl, substituted or non-substituted C 2 -C 8 -alkenyl, substituted or non-substituted C2-C 8 -alkynyl, substituted or non-substituted Ci -C 8 -alkoxy;
• Y 1 to Y 5 independently represent a hydrogen atom, a halogen atom, a nitro group, a a cyano group, a substituted or non-substituted carbaldehyde 0-(Ci -C 8 -alkyl)oxime, a pentafluoro- 6 -sulfenyl group, substituted or non-substituted CrC 8 -alkyl, substituted or non-substituted C 3 -C 8 -cycloalkyl, substituted or non-substituted CrC 8 -halogenoalkyl having 1 to 5 halogen atoms, a C 2 -C 8 -alkenyl, substituted or non-substituted C 2 -C 8 -alkynyl, substituted or non-substituted CrC 8 -alkoxy, substituted or non- substituted CrC 8 -halogenoalkoxy having 1 to 5 halogen atom
• any of the compounds according to the invention can exist as one or more stereoisomers depending on the number of stereogenic units (as defined by the lU PAC rules) in the compound.
• the invention thus relates equally to all the stereoisomers, and to the mixtures of all the possible stereoisomers, in all proportions.
• the stereoisomers can be separated according to the methods which are known per se by the man ordinary skilled in the art.
• the stereostructure of the oxime moiety present in the 4-substituted-3- ⁇ phenyl[(heterocyclylmethoxy)imino]methyl ⁇ -1 ,2,4-oxadiazol-5(4H)-one derivative of formula (I) includes (E) or (Z) isomer, and these stereoisomers form part of the present invention.
• halogen means fluorine, chlorine, bromine or iodine ;
• ⁇ heteroatom can be nitrogen, oxygen or sulfur ;
• a group or a substituent that is substituted according to the invention can be substituted by one or more of the following groups or atoms: a halogen atom, a nitro group, a hydroxy group, a cyano group, an amino group, a sulfenyl group, a pentafluoro-A 6 -sulfenyl group, a formyl group, a carbaldehyde 0-(Ci-C 8 -alkyl)oxime, a formyloxy group, a formylamino group, a formylamino group, a (hydroxyimino)-Ci-C 6 -alkyl group, a CrC 8 -alkyl, a tri(CrC 8 -alkyl)silyl, C 3 -C 8 -cycloalkyl, C 3 -C 8 -cycloalkenyl, a CrC 8 - halogenoalkyl having 1
• a group or a substituent that is substituted according to the invention can be substituted in a way that substituting groups form together a substituted or non-substituted, saturated or partially saturated 3-, 4-, 5-, 6-, 7-, 8-, 9-, 10-, or 1 1 -membered cycle, which can be a carbocycle or a heterocycle comprising up to 4 heteroatoms selected from the list consisting of N, O, and S
• aryl means phenyl or naphthyl
• heterocyclyl means fused or non-fused, saturated or unsaturated, 4-, 5-, 6-, 7-, 8-, 9-, 1 0-, 1 1 - or 12-membered ring comprising up to 4 heteroatoms selected in the list consisting of N, O, S.
• Preferred compounds of formula (I) according to the invention are those wherein X 1 represents substituted or non-substituted CrC 8 -alkyl, substituted or non-substituted C 3 -C 8 -cycloalkyl or a substituted or non-substituted C 2 -C 8 -alkenyl.
• More preferred compounds of formula (I) according to the invention are those wherein X 1 represents a methyl group, an ethyl group, a n-propyl group, an isopropyl group or a cyclopropyl group.
• Z 1 represents a hydrogen atom, a halogen atom, a nitro group, an amino group, an hydroxyamino group, substituted or non-substituted Ci -C 8 -alkoxyamino group, substituted or non-substituted Ci -C 8 -alkylamino, substituted or non-substituted C3-Cio-cycloalkylamino, substituted or non-substituted C3-C10- cycloalkenylamino, substituted or non-substituted C 5 -Ci 2 -fused bicycloalkylamino, substituted or non- substituted C 5 -Ci2-fused bicycloalkenylamino, substituted or non-substituted di-CrC 8 -alkylamino, substituted or non-substituted phenylamino, substituted or non-substituted phenylamino, substituted or non-sub
• other preferred compounds of formula (I) according to the invention are those wherein R a represents a hydrogen atom, a hydroxy group, substituted or non-substituted CrC 8 -alkyl, substituted or non-substituted C 3 -C 8 -cycloalkyl, substituted or non-substituted Ci -C 8 -alkoxy.
• more preferred compounds of formula (I) according to the invention are those wherein R a represents a hydrogen atom.
• more preferred compounds of formula (I) according to the invention are those wherein Q represents a substituted or non-substituted C 4 -C 8 -alkyl, substituted or non-substituted C 3 -C 8 -cycloalkyl, substituted or non-substituted -C 8 -alkynyl, substituted or non-substituted C 4 -C 8 -alkoxy, substituted or non-substituted C 4 -C 8 -alkenyloxy, substituted or non-substituted C 4 -C 8 -alkynyloxy, substituted or non-substituted C 3 -C 8 -alkylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted heterocyclyl.
• Q represents a substituted or non- substituted C 4 -C 8 -alkyl, substituted or non-substituted C 3 -C 8 -cycloalkyl, substituted or non-substituted C 4 -C 8 -alkynyl, substituted or non-substituted C 4 -C 8 -alkoxy, substituted or non-substituted C 4 -C 8 - alkenyloxy, substituted or non-substituted C -C 8 -alkynyloxy, substituted or non-substituted C 3 -C 8 - alkylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted heterocyclyl
• substituents are chosen in the list of a halogen atom
• Q represents a substituted or non- substituted C -C 8 -alkyl, substituted or non-substituted C 3 -C 8 -cycloalkyl, substituted or non-substituted C 4 -C 8 -alkynyl, substituted or non-substituted C 4 -C 8 -alkoxy, substituted or non-substituted C 4 -C 8 - alkenyloxy, substituted or non-substituted C -C 8 -alkynyloxy, substituted or non-substituted C 3 -C 8 - alkylsulfenyl, substituted or non-substituted aryl, substituted or non-substituted heterocyclyl.
• substituents are chosen in the list of a halogen atom
• even more preferred compounds of formula (I) according to the invention are those wherein Q represents a substituted or non-substituted C 4 -C 8 -alkyl, substituted or non-substituted C 4 -C 8 -alkynyl, substituted or non-substituted C 4 -C 8 -alkoxy, substituted or non-substituted C 4 -C 8 -alkenyloxy, substituted or non-substituted C -C 8 -alkynyloxy, substituted or non-substituted aryl, substituted or non-substituted heterocyclyl.
• Z 2 represents a hydrogen atom, a halogen atom, substituted or non-substituted Ci -C 8 -alkyl.
• More preferred compounds of formula (I) according to the invention are those wherein Z 2 represents a hydrogen atom.
• Y 1 to Y 5 independently represent a hydrogen atom, a halogen atom, substituted or non-substituted CrC 8 -alkyl, substituted or non-substituted C 3 -C 8 -cycloalkyl, substituted or non-substituted CrC 8 -halogenoalkyl having 1 to 5 halogen atoms, substituted or non-substituted CrC 8 -alkoxy.
• More preferred compounds of formula (I) according to the invention are those wherein Y 1 to Y 5 independently represent a hydrogen atom, a halogen atom, methyl, ethyl, isopropyl, isobutyl, tertbutyl, trifluoromethyl, difluoromethyl, allyl, ethynyl, propargyl, cyclopropyl, methoxy or trifluoromethoxy.
• Even more preferred compounds of formula (I) according to the invention are those wherein Y 1 to Y 5 independently represent a hydrogen atom or fluorine atom.
• X 1 with preferred features of one or more of Zi , Z 2 , Y 1 to Y 5 ;
• Y 1 with preferred features of one or more of Zi , Z2, X 1 , Y 2 to Y 5 ;
• preferred features of Y 2 with preferred features of one or more of Zi , Z 2 , X 1 , Y 1 , Y 3 , Y 4 , Y 5 ; preferred features of Y 3 with preferred features of one or more of Zi , Z 2 , X 1 , Y 1 , Y 2 , Y 4 , Y 5 ; preferred features of Y 4 with preferred features of one or more of Zi , Z2, X 1 , Y 1 , Y 2 , Y 3 , Y 5 ; preferred features of Y 5 with preferred features of one or more of Zi , Z 2 , X 1 , Y 1 , Y 2 , Y 3 , Y 4 ; In these combinations of preferred features of the substituents of the compounds according to the invention, the said preferred features can also be selected among the more preferred features of each of Z Z 2 , X 1 and Y 1 to Y 5 ; so as to form most preferred subclasses of compounds according to the invention.
• the present invention also relates to a process for the preparation of compounds of formula (I).
• LG independently represents a leaving group.
• Suitable leaving groups can be selected in the list consisting of a halogen atom or other customary nucleofugal groups such as triflate, mesylate, or tosylate.
• Suitable phosgene equivalent for the conversion of compounds of formula (V) into a compound of formula (I) can be chosen as being phosgene, diphosgene, triphosgene, carbonyl di-imidazole, a chlorformate derivative, such as ethyl chloroformate and 4-nitrophenoxy-chloroformate.
• process P1 according to the invention can be completed by a further step comprising the additional modification of this group, notably by a reaction of acylation, alkoxycarbonylation, alkylaminocarbonylation, (thio)acylation, alkoxy(thio)carbonylation, alkylsuphenyl(thio)carbonylation or alkylamino(thio)carbonylation to yield to a compound of formula (lb), according to known methods.
• acylation, alkoxycarbonylation, alkylaminocarbonylation, (thio)acylation, alkoxy(thio)carbonylation, alkylsuphenyl(thio)carbonylation or alkylamino(thio)carbonylation to yield to a compound of formula (lb), according to known methods.
• a process P2 according to the invention and such a process P2 can be illustrated by the following reaction scheme:
• LG' represents a leaving group.
• Suitable leaving groups can be selected in the list consisting of a halogen atom or other customary nucleofugal groups such as 440ate, hydroxide or cyanide.
• a further process P3 for the preparation of compounds of formula (Id) from compounds of formula (Ic), by a reaction of nucleophilic substitution to yield to a compound of formula (Id), optionally in the presence of a catalyst notably a transition metal catalyst, such as palladium salts or complexes for example palladium (I I) chloride, palladium (II) acetate, tetrakis-(triphenylphosphine) palladium(O), bis-(triphenylphosphine) palladium dichloride (I I), tris(dibenzylideneacetone) dipalladium(O), bis(dibenzylideneacetone) palladium(O) or 1 , 1 '-bis(diphenylphosphino)ferrocene-palladium (I I) chloride.
• a catalyst notably a transition metal catalyst, such as palladium salts or complexes for example palladium (I I) chloride, palladium
• the palladium complex is directly generated in the reaction mixture by separately adding to the reaction mixture a palladium salt and a complex ligand such as a phosphine, for example triethylphosphine, tri- tert-butylphosphine, tricyclohexylphosphine, 2-(dicyclohexylphosphine)biphenyl, 2-(di-tert- butylphosphin)biphenyl, 2-(dicyclohexylphosphine)-2'-(N,N-dimethylamino)-biphenyl, triphenylphosphine, tris-(o-tolyl)phosphine, sodium 3-(diphenylphosphino)benzolsulfonate, tris-2- (methoxyphenyl)phosphine, 2,2'-bis-(diphenylphosphine)-1 ,1 '-binaphthyl, 1
• a base such as an inorganic or an organic base
• a base such as an inorganic or an organic base
• a base such as an inorganic or an organic base
• a base such as an inorganic or an organic base
• a base such as an inorganic or an organic base
• a base such as an inorganic or an organic base
• a base such as an inorganic or an organic base
• a base such as an inorganic or an organic base
• a base such as an inorganic or an organic base
• a base such as an inorganic or an organic base
• Z 1 a represents a halogen atom
• Z 1 b represents a cyano group, substituted or non-substituted Ci -C 8 -alkoxyamino group, substituted or non-substituted Ci -Cs-alkylamino, substituted or non-substituted C3-Cio-cycloalkylamino, substituted or non- substituted C 3 -Ci 0 -cycloalkenylamino, substituted or non-substituted C 5 -Ci 2 -fused bicycloalkylamino, substituted or non-substituted C 5 -Ci 2 -fused bicycloalkenylamino, substituted or non-substituted di- Ci -Cs-alkylamino, substituted or non-substituted
• process P1 according to the invention can be completed by a further step comprising the additional modification of this group, notably by a reaction of thiocarbonylation in the presence of a thiocarbonylating agent such as 2, 4-bis(4-methoxyphenyl)-1 ,3,2,4-dithiadiphosphetane 2,4-disulfide, phosphorus pentasulfide, sulfur to yield to a compound of formula (If), according to known methods.
• a thiocarbonylating agent such as 2, 4-bis(4-methoxyphenyl)-1 ,3,2,4-dithiadiphosphetane 2,4-disulfide, phosphorus pentasulfide, sulfur to yield to a compound of formula (If), according to known methods.
• Y 1 , Y 2 , Y 3 , Y 4 Y 5 , X 1 , Z 2 , R a and Q are as herein-defined;
• R represents optionally substituted Ci -C 8 -alkyl, C2-C8-alkenyl, C2-C 8 -alkynyl, C3-Cio-cycloalkyl, C 3 -Ci 0 -cycloalkenyl, C 3 -Ci 0 -fused bicycloalkyl, C 5 -Ci 2 -fused bicycloalkenyl
• LG represents a leaving group
• Suitable leaving groups can be selected in the list consisting of a halogen atom or other customary nucleofugal groups such as 440, 44, 46, 47, 48, 49, 50, 51, 52, 52, 53, 52, 53, 52, 53, 52, 53, 52, 53, 54, 55, 56, 55, 56, 56, 56, 56, 56, 56, 56, 56, 56, 56, 57, 59, 58, 59, 59, 59, 59, 59, 59, 59, 59, 59, 59, 59, 59, 59, 59, 60, 60, 60, 60, 60, 60, 60, 60, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61, 61,
• Z 1 f represents a group of formula Z 1 e -PG wherein Z 1 e represents an amino group, an hydroxyamino group, a substituted or non-substituted Ci -C 8 -alkoxyamino, substituted or non- substituted d-Cs-alkylamino, a substituted or non-substituted C2-C 8 -alkenylamino, substituted or non-substituted C2-C8-alkynylamino, substituted or non-substituted C3-Cio-cycloalkylamino, substituted or non-substituted C 3 -Ci 0 -cycloalkenylamino, substituted or non-substituted C 5 - Ci2-fused bicycloalkylamino, substituted or non-substituted C 5 -Ci 2 -fused bicycloalkenylamino, substituted or non-substituted di-C
• Z 1 g represents an amino group, a substituted or non-substituted Ci-Cs-alkylamino
• Z 1 h represents a substituted or non-substituted Ci-Cs-alkylamino, substituted or non- substituted di-d-Cs-alkylamino.
• Y 1 , Y 2 , Y 3 , Y 4 Y 5 , Z 2 , X 1 , R a are as herein-defined;
• Q' represents substituted or non-substituted CrC 8 -alkoxy, substituted or non-substituted C 2 -C 8 -alkenyloxy, substituted or non-substituted C 2 -C 8 -alkynyloxy, substituted or non- substituted Ci-Cs-alkylsulfenyl, substituted or non-substituted C2-Cs-alkenylsulfenyl, substituted or non-substituted C2-C8-alkynylsulfenyl, substituted or non-substituted arylsulfenyl, substituted or non-substituted cycloalkoxy; substituted or non-substituted cycloalkenyloxy, substituted or non-substituted aryloxy; substituted or non-substituted heterocyclyloxy, substituted or non-substituted C 5 -Ci 2 -fused
• LGi and LG 2 represent leaving group
• Suitable leaving groups can be selected in the list consisting of a halogen atom or other customary nucleofugal groups such as imidazole, halogenophenoxide or the likes.
• processes P1 to P8 can be performed if appropriate in the presence of a solvent and if appropriate in the presence of a base.
• processes P1 and P2 can be performed if appropriate in the presence of a catalyst.
• Suitable catalyst can be chosen as being 4-dimethyl-aminopyridine, 1 -hydroxy-benzotriazole or dimethylformamide.
• the process P2 according to the present invention can be performed in the presence of condensing agent.
• Suitable condensing agent can be chosen as being acid halide former, such as phosgene, phosphorous tri-bro-mide, phosphorous trichloride, phosphorous pentachloride, phosphorous trichloride oxide or thionyl chloride ; anhydride former, such as ethyl chloroformate, methyl chloroformate, isopropyl chloroformate, isobutyl chloroformate or methanesulfonyl chloride ; carbodiimides, such as ⁇ , ⁇ '-dicyclohexylcarbodiimide (DCC) or other customary condensing agents, such as phosphorous pentoxide, polyphosphoric acid, N,N'-carbonyl- diimidazole, 2-ethoxy-N-ethoxycarbonyl-1 ,2-dihydroquino
• Suitable solvents for carrying out processes P1 to P8 according to the invention are customary inert organic solvents. Preference is given to using optionally halogenated aliphatic, alicyclic or aromatic hydrocarbons, such as petroleum ether, hexane, heptane, cyclohexane, methylcyclohexane, benzene, toluene, xylene or decalin ; chlorobenzene, dichlorobenzene, dichloromethane, chloroform, carbon tetrachloride, dichlorethane or trichlorethane ; ethers, such as diethyl ether, diisopropyl ether, methyl tert-butyl ether, methyl tert-amyl ether, dioxane, tetrahydrofuran, 1 ,2-dimethoxyethane, 1 ,2- diethoxyethane or anisole ; nitriles, such as
• Suitable bases for carrying out processes P1 to P8 according to the invention are inorganic and organic bases which are customary for such reactions.
• alkaline earth metal alkali metal hydride, alkali metal hydroxides or alkali metal alkoxides, such as sodium hydroxide, sodium hydride, calcium hydroxide, potassium hydroxide, potassium tert-butoxide or other ammonium hydroxide
• alkali metal carbonates such as sodium carbonate, potassium carbonate, potassium bicarbonate, sodium bicarbonate, cesium carbonate
• alkali metal or alkaline earth metal acetates such as sodium acetate, potassium acetate, calcium acetate and also tertiary amines, such as trimethylamine, triethylamine, diisopropylethylamine, tributylamine, /V, /V-dimethylaniline, pyridine, /V-methylpiperidine, /V,/V-dimethylaminopyridine
• reaction temperature can independently be varied within a relatively wide range.
• process P1 according to the invention is carried out at temperatures between -20 °C and ⁇ 60 °C.
• Processes P1 to P8 according to the invention are generally independently carried out under atmospheric pressure. However, it is also possible to operate under elevated or reduced pressure.
• reaction mixture is treated with water and the organic phase is separated off and, after drying, concentrated under reduced pressure. If appropriate, the remaining residue can be freed by customary methods, such as chromatography or recrystallization, from any impurities that can still be present.
• the present invention thus provides compounds of formula (V) useful as intermediate compounds or materials for the process of preparation according to the invention
• Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , X 1 , Z 1 and Z 2 are as herein-defined.
• Preferred intermediates are compounds of formula (V) according to the invention wherein X 1 represents substituted or non-substituted CrC 8 -alkyl.
• the present invention also relates to a fungicide composition
• a fungicide composition comprising an effective and non-phytotoxic amount of an active compound of formula (I).
• fungicide composition comprising, as an active ingredient, an effective amount of a compound of formula (I) as herein defined and an agriculturally acceptable support, carrier or filler.
• the term "support” denotes a natural or synthetic organic or inorganic compound with which the active compound of formula (I) is combined or associated to make it easier to apply, notably to the parts of the plant.
• This support is thus generally inert and should be agriculturally acceptable.
• the support can be a solid or a liquid.
• suitable supports include clays, natural or synthetic silicates, silica, resins, waxes, solid fertilisers, water, alcohols, in particular butanol organic solvents, mineral and plant oils and derivatives thereof. Mixtures of such supports can also be used.
• composition according to the invention can also comprise additional components.
• the composition can further comprise a surfactant.
• the surfactant can be an emulsifier, a dispersing agent or a wetting agent of ionic or non-ionic type or a mixture of such surfactants.
• polyacrylic acid salts lignosulfonic acid salts, phenolsulfonic or naphthalenesulfonic acid salts
• polycondensates of ethylene oxide with fatty alcohols or with fatty acids or with fatty amines substituted phenols (in
• the presence of at least one surfactant is generally essential if the active compound and/or the inert support are water-insoluble and if the vector agent for the application is water.
• surfactant content can be comprised from 5% to 40% by weight of the composition.
• additional components can also be included, e.g. protective colloids, adhesives, thickeners, thixotropic agents, penetration agents, stabilisers, sequestering agents.
• the active compounds can be combined with any solid or liquid additive, which complies with the usual formulation techniques.
• composition according to the invention can contain from 0.05 to 99% by weight of active compound, preferably 1 0 to 70% by weight.
• compositions according to the invention can be used in various forms and formulations such as aerosol dispenser, capsule suspension, cold fogging concentrate, dustable powder, emulsifiable concentrate, emulsion oil in water, emulsion water in oil, encapsulated granule, fine granule, flowable concentrate for seed treatment, gas (under pressure), gas generating product, granule, hot fogging concentrate, macrogranule, microgranule, oil dispersible powder, oil miscible flowable concentrate, oil miscible liquid, paste, plant rodlet, powder for dry seed treatment, seed coated with a pesticide, soluble concentrate, soluble powder, solution for seed treatment, suspension concentrate (flowable concentrate), ultra low volume (ULV) liquid, ultra low volume (ULV) suspension, water dispersible granules or tablets, water dispersible powder for slurry treatment, water soluble granules or tablets, water soluble powder for seed treatment and wettable powder.
• These compositions include not only compositions which are ready to be applied to the plant
• the formulations can be prepared in a manner known per se, for example by mixing the active ingredients with at least one customary extender, solvent or diluent, adjuvant, emulsifier, dispersant, and/or binder or fixative, wetting agent, water repellent, if appropriate desiccants and UV stabilizers and, if appropriate, dyes and pigments, antifoams, preservatives, inorganic and organic thickeners, adhesives, gibberellins and also further processing auxiliaries and also water.
• further processing steps are necessary, e.g. wet grinding, dry grinding and granulation.
• inventive active ingredients may be present as such or in their (commercial) formulations and in the use forms prepared from these formulations as a mixture with other (known) active ingredients, such as insecticides, attractants, sterilants, bactericides, acaricides, nematodes, fungicides, growth regulators, herbicides, fertilizers, safeners, biological and/or semiochemicals.
• active ingredients such as insecticides, attractants, sterilants, bactericides, acaricides, nematodes, fungicides, growth regulators, herbicides, fertilizers, safeners, biological and/or semiochemicals.
• the present invention further relates to the use of compounds of the formula (I) as herein defined for the control of phytopathogenic fungi.
• the present invention further relates to the use of compounds of the formula (I) as herein defined for the treatment of transgenic plants.
• the present invention further relates to the use of compounds of the formula (I) as herein defined for the treatment of seed and of seed of transgenic plants.
• the present invention further relates to a process for producing compositions for controlling phytopathogenic harmful fungi, characterized in that derivatives of the formula (I) as herein defined are mixed with extenders and/or surfactants.
• a method for controlling the phytopathogenic fungi of plants, crops or seeds characterized in that an agronomically effective and substantially non-phytotoxic quantity of a pesticide composition according to the invention is applied as seed treatment, foliar application, stem application, drench or drip application (chemigation) to the seed, the plant or to the fruit of the plant or to soil or to inert substrate (e.g.
• inorganic substrates like sand, rockwool, glasswool; expanded minerals like perlite, vermiculite, zeolite or expanded clay), Pumice, Pyroclastic materials or stuff, synthetic organic substrates (e.g. polyurethane) organic substrates (e.g. peat, composts, tree waste products like coir, wood fibre or chips, tree bark) or to a liquid substrate (e.g. floating hydroponic systems, Nutrient Film Technique, Aeroponics) wherein the plant is growing or wherein it is desired to grow.
• synthetic organic substrates e.g. polyurethane
• organic substrates e.g. peat, composts, tree waste products like coir, wood fibre or chips, tree bark
• liquid substrate e.g. floating hydroponic systems, Nutrient Film Technique, Aeroponics
• the method according to the invention can either be a curing, preventing or eradicating method.
• a composition used can be prepared beforehand by mixing the two or more active compounds according to the invention.
• ⁇ for foliar treatments from 0.1 to 10,000 g/ha, preferably from 10 to 1 ,000 g/ha, more preferably from 50 to 300g/ha; in case of drench or drip application, the dose can even be reduced, especially while using inert substrates like rockwool or perlite;
• ⁇ for soil treatment from 0.1 to 1 0,000 g/ha, preferably from 1 to 5,000 g/ha.
• a lower dose can offer adequate protection.
• Certain climatic conditions, resistance or other factors like the nature of the phytopathogenic fungi or the degree of infestation, for example, of the plants with these fungi, can require higher doses of combined active ingredients.
• the optimum dose usually depends on several factors, for example on the type of phytopathogenic fungus to be treated, on the type or level of development of the infested plant, on the density of vegetation or alternatively on the method of application.
• the crop treated with the pesticide composition or combination according to the invention is, for example, grapevine, but this could be cereals, vegetables, lucerne, soybean, market garden crops, turf, wood, tree or horticultural plants.
• the method of treatment according to the invention can also be useful to treat propagation material such as tubers or rhizomes, but also seeds, seedlings or seedlings pricking out and plants or plants pricking out. This method of treatment can also be useful to treat roots.
• the method of treatment according to the invention can also be useful to treat the over-ground parts of the plant such as trunks, stems or stalks, leaves, flowers and fruit of the concerned plant.
• cotton Among the plants that can be protected by the method according to the invention, mention can be made of cotton; flax; vine; fruit or vegetable crops such as Rosaceae sp. (for instance pip fruit such as apples and pears, but also stone fruit such as apricots, almonds and peaches), Ribesioidae sp., Juglandaceae sp., Betulaceae sp., Anacardiaceae sp., Fagaceae sp., Moraceae sp., Oleaceae sp., Actinidaceae sp., Lauraceae sp., Musaceae sp.
• Rosaceae sp. for instance pip fruit such as apples and pears, but also stone fruit such as apricots, almonds and peaches
• Rosaceae sp. for instance pip fruit such as apples and pears, but also stone fruit such as apricots, almonds and peaches
• Rubiaceae sp. for instance banana trees and plantins
• Rubiaceae sp. Theaceae sp., Sterculiceae sp., Rutaceae sp. (for instance lemons oranges and grapefruit); Solanaceae sp. (for instance tomatoes), Liliaceae sp., Asteraceae sp. (for instance lettuces), Umbelliferae sp., Cruciferae sp., Chenopodiaceae sp., Cucurbitaceae sp., Papilionaceae sp. (for instance peas), Rosaceae sp. (for instance strawberries); major crops such as Graminae sp.
• Asteraceae sp. for instance sunflower
• Cruciferae sp. for instance colza
• Fabacae sp. for instance peanuts
• Papilionaceae sp. for instance soybean
• Solanaceae sp. for instance potatoes
• Chenopodiaceae sp. for instance beetroots
• horticultural and forest crops as well as genetically modified homologues of these crops.
• the method of treatment according to the invention can be used in the treatment of genetically modified organisms (GMOs), e.g. plants or seeds.
• GMOs genetically modified organisms
• Genetically modified plants are plants of which a heterologous gene has been stably integrated into genome.
• the expression "heterologous gene” essentially means a gene which is provided or assembled outside the plant and when introduced in the nuclear, chloroplastic or mitochondrial genome gives the transformed plant new or improved agronomic or other properties by expressing a protein or polypeptide of interest or by downregulating or silencing other gene(s) which are present in the plant (using for example, antisense technology, cosuppression technology, RNA interference - RNAi - technology or microRNA - miRNA - technology).
• a heterologous gene that is located in the genome is also called a transgene.
• a transgene that is defined by its particular location in the plant genome is called a transformation or transgenic event.
• the treatment according to the invention may also result in superadditive (“synergistic") effects.
• superadditive for example, reduced application rates and/or a widening of the activity spectrum and/or an increase in the activity of the active compounds and compositions which can be used according to the invention, better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to water or soil salt content, increased flowering performance, easier harvesting, accelerated maturation, higher harvest yields, bigger fruits, larger plant height, greener leaf color, earlier flowering, higher quality and/or a higher nutritional value of the harvested products, higher sugar concentration within the fruits, better storage stability and/or processability of the harvested products are possible, which exceed the effects which were actually to be expected.
• the active compound combinations according to the invention may also have a strengthening effect in plants. Accordingly, they are also suitable for mobilizing the defense system of the plant against attack by unwanted microorganisms. This may, if appropriate, be one of the reasons of the enhanced activity of the combinations according to the invention, for example against fungi.
• Plant- strengthening (resistance-inducing) substances are to be understood as meaning, in the present context, those substances or combinations of substances which are capable of stimulating the defense system of plants in such a way that, when subsequently inoculated with unwanted microorganisms, the treated plants display a substantial degree of resistance to these microorganisms.
• unwanted microorganisms are to be understood as meaning phytopathogenic fungi, bacteria and viruses.
• the substances according to the invention can be employed for protecting plants against attack by the abovementioned pathogens within a certain period of time after the treatment.
• the period of time within which protection is effected generally extends from 1 to 10 days, preferably 1 to 7 days, after the treatment of the plants with the active compounds.
• Plants and plant cultivars which are preferably to be treated according to the invention include all plants which have genetic material which impart particularly advantageous, useful traits to these plants (whether obtained by breeding and/or biotechnological means).
• Plants and plant cultivars which are also preferably to be treated according to the invention are resistant against one or more biotic stresses, i.e. said plants show a better defense against animal and microbial pests, such as against nematodes, insects, mites, phytopathogenic fungi, bacteria, viruses and/or viroids.
• nematode resistant plants are described in e.g. US Patent Application Nos 1 1 /765,491 , 1 1 /765,494, 1 0/926,81 9, 1 0/782,020, 12/032,479, 1 0/783,41 7, 1 0/782,096, 1 1 /657,964, 12/1 92,904, 1 1 /396,808, 12/1 66,253, 12/1 66,239, 12/1 66, 124, 12/166,209, 1 1 /762,886, 12/364,335, 1 1 /763,947, 12/252,453, 12/209,354, 12/491 ,396, 12/497,221 , 12/644,632, 12/646,004, 12/701 ,058, 12/71 8,059, 12/721 ,595, 12/638,591 and in W01 1 /002992, W01 1 /014749, W01 1 /1 03247, W01 1 /
• Plants and plant cultivars which may also be treated according to the invention are those plants which are resistant to one or more abiotic stresses.
• Abiotic stress conditions may include, for example, drought, cold temperature exposure, heat exposure, osmotic stress, flooding, increased soil salinity, increased mineral exposure, ozone exposure, high light exposure, limited availability of nitrogen nutrients, limited availability of phosphorus nutrients, shade avoidance.
• Plants and plant cultivars which may also be treated according to the invention are those plants characterized by enhanced yield characteristics. Increased yield in said plants can be the result of, for example, improved plant physiology, growth and development, such as water use efficiency, water retention efficiency, improved nitrogen use, enhanced carbon assimilation, improved photosynthesis, increased germination efficiency and accelerated maturation.
• Yield can furthermore be affected by improved plant architecture (under stress and non-stress conditions), including but not limited to, early flowering, flowering control for hybrid seed production, seedling vigor, plant size, internode number and distance, root growth, seed size, fruit size, pod size, pod or ear number, seed number per pod or ear, seed mass, enhanced seed filling, reduced seed dispersal, reduced pod dehiscence and lodging resistance.
• Further yield traits include seed composition, such as carbohydrate content, protein content, oil content and composition, nutritional value, reduction in anti-nutritional compounds, improved processability and better storage stability.
• Plants that may be treated according to the invention are hybrid plants that already express the characteristic of heterosis or hybrid vigor which results in generally higher yield, vigor, health and resistance towards biotic and abiotic stresses). Such plants are typically made by crossing an inbred male-sterile parent line (the female parent) with another inbred male-fertile parent line (the male parent). Hybrid seed is typically harvested from the male sterile plants and sold to growers. Male sterile plants can sometimes (e.g. in corn) be produced by detasseling, i.e. the mechanical removal of the male reproductive organs (or males flowers) but, more typically, male sterility is the result of genetic determinants in the plant genome.
• Male sterile plants can also be obtained by plant biotechnology methods such as genetic engineering.
• a particularly useful means of obtaining male-sterile plants is described in WO 89/1 0396 in which, for example, a ribonuclease such as barnase is selectively expressed in the tapetum cells in the stamens. Fertility can then be restored by expression in the tapetum cells of a ribonuclease inhibitor such as barstar (e.g. WO 91 /02069).
• Plants or plant cultivars obtained by plant biotechnology methods such as genetic engineering
• Such plants can be obtained either by genetic transformation, or by selection of plants containing a mutation imparting such herbicide tolerance.
• Herbicide-resistant plants are for example glyphosate-tolerant plants, i.e. plants made tolerant to the herbicide glyphosate or salts thereof. Plants can be made tolerant to glyphosate through different means.
• glyphosate-tolerant plants can be obtained by transforming the plant with a gene encoding the enzyme 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS).
• EPSPS 5-enolpyruvylshikimate-3-phosphate synthase
• EPSPS 5-enolpyruvylshikimate-3-phosphate synthase
• Glyphosate-tolerant plants can also be obtained by expressing a gene that encodes a glyphosate oxido-reductase enzyme as described in U.S. Patent Nos. 5,776,760 and 5,463, 1 75. Glyphosate-tolerant plants can also be obtained by expressing a gene that encodes a glyphosate acetyl transferase enzyme as described in for example WO 02/36782, WO 03/092360, WO 05/012515 and WO 07/024782. Glyphosate-tolerant plants can also be obtained by selecting plants containing naturally-occurring mutations of the above- mentioned genes, as described in for example WO 01 /024615 or WO 03/013226.
• Plants comprising other genes that confer glyphosate tolerance are described in e.g. US patent applications 1 1 /588,81 1 , 1 1 /1 85,342, 12/364,724, 1 1 /1 85,560 or 12/423,926.
• Other herbicide resistant plants are for example plants that are made tolerant to herbicides inhibiting the enzyme glutamine synthase, such as bialaphos, phosphinothricin or glufosinate.
• Such plants can be obtained by expressing an enzyme detoxifying the herbicide or a mutant glutamine synthase enzyme that is resistant to inhibition, e.g. described in US Patent Application No 1 1 /760,602.
• One such efficient detoxifying enzyme is an enzyme encoding a phosphinothricin acetyltransferase (such as the bar or pat protein from Streptomyces species). Plants expressing an exogenous phosphinothricin acetyltransferase are for example described in U.S. Patent Nos. 5,561 ,236; 5,648,477; 5,646,024; 5,273,894; 5,637,489; 5,276,268; 5,739,082; 5,908,81 0 and 7, 1 12,665.
• HPPD hydroxyphenylpyruvatedioxygenase
• Plants tolerant to H PPD-inhibitors can be transformed with a gene encoding a naturally-occurring resistant HPPD enzyme, or a gene encoding a mutated or chimeric HPPD enzyme as described in WO 96/38567, WO 99/24585, WO 99/24586, WO 2009/144079, WO 2002/046387, or US 6,768,044, W01 1 /076877, W01 1 /076882, W01 1 /076885, W01 1 /076889, W01 1 /076892.
• Tolerance to HPPD-inhibitors can also be obtained by transforming plants with genes encoding certain enzymes enabling the formation of homogentisate despite the inhibition of the native HPPD enzyme by the HPPD-inhibitor. Such plants and genes are described in WO 99/34008 and WO 02/36787. Tolerance of plants to H PPD inhibitors can also be improved by transforming plants with a gene encoding an enzyme having prephenate deshydrogenase (PDH) activity in addition to a gene encoding an H PPD-tolerant enzyme, as described in WO 2004/024928.
• PDH prephenate deshydrogenase
• plants can be made more tolerant to H PPD-inhibitor herbicides by adding into their genome a gene encoding an enzyme capable of metabolizing or degrading HPPD inhibitors, such as the CYP450 enzymes shown in WO 2007/1 03567 and WO 2008/150473.
• an enzyme capable of metabolizing or degrading HPPD inhibitors such as the CYP450 enzymes shown in WO 2007/1 03567 and WO 2008/150473.
• Still further herbicide resistant plants are plants that are made tolerant to acetolactate synthase (ALS) inhibitors.
• ALS-inhibitors include, for example, sulfonylurea, imidazolinone, triazolopyrimidines, pryimidinyoxy(thio)benzoates, and/or sulfonylaminocarbonyltriazolinone herbicides.
• Different mutations in the ALS enzyme also known as acetohydroxyacid synthase, AHAS
• AHAS acetohydroxyacid synthase
• imidazolinone-tolerant plants are also described in for example WO 2004/040012, WO 2004/1 06529, WO 2005/020673, WO 2005/093093, WO 2006/007373, WO 2006/015376, WO 2006/024351 , and WO 2006/060634. Further sulfonylurea- and imidazolinone-tolerant plants are also described in for example WO 07/024782, W01 1 /076345, WO2012058223 and US Patent Application No 61 /288958.
• plants tolerant to imidazolinone and/or sulfonylurea can be obtained by induced mutagenesis, selection in cell cultures in the presence of the herbicide or mutation breeding as described for example for soybeans in U.S. Patent 5,084,082, for rice in WO 97/4121 8, for sugar beet in U.S. Patent 5,773,702 and WO 99/057965, for lettuce in U.S. Patent 5, 198,599, or for sunflower in WO 01 /065922.
• Plants or plant cultivars obtained by plant biotechnology methods such as genetic engineering which may also be treated according to the invention are insect-resistant transgenic plants, i.e. plants made resistant to attack by certain target insects. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation imparting such insect resistance.
• An "insect-resistant transgenic plant”, as used herein, includes any plant containing at least one transgene comprising a coding sequence encoding:
• an insecticidal crystal protein from Bacillus thuringiensis or an insecticidal portion thereof such as the insecticidal crystal proteins listed by Crickmore et al. (1 998, Microbiology and Molecular Biology Reviews, 62: 807-813), updated by Crickmore et al. (2005) at the Bacillus thuringiensis toxin nomenclature, online at: http://www.lifesci. Hampshire.
• insecticidal portions thereof e.g., proteins of the Cry protein classes Cryl Ab, Cryl Ac, Cryl B, Cryl C, Cryl D, Cryl F, Cry2Ab, Cry3Aa, or Cry3Bb or insecticidal portions thereof (e.g. EP 1 999141 and WO 2007/1 07302), or such proteins encoded by synthetic genes as e.g. described in and US Patent Application No 12/249,01 6 ; or
• a crystal protein from Bacillus thuringiensis or a portion thereof which is insecticidal in the presence of a second other crystal protein from Bacillus thuringiensis or a portion thereof, such as the binary toxin made up of the Cry34 and Cry35 crystal proteins (Moellenbeck et al. 2001 , Nat. Biotechnol. 1 9: 668-72; Schnepf et al. 2006, Applied Environm. Microbiol. 71 , 1 765-1 774) or the binary toxin made up of the Cryl A or Cry1 F proteins and the Cry2Aa or
• a hybrid insecticidal protein comprising parts of different insecticidal crystal proteins from Bacillus thuringiensis, such as a hybrid of the proteins of 1 ) above or a hybrid of the proteins of 2) above, e.g., the Cry1 A.1 05 protein produced by corn event MON89034 (WO 2007/027777) ; or
• VI P vegetative insecticidal
• a secreted protein from Bacillus thuringiensis or Bacillus cereus which is insecticidal in the presence of a second secreted protein from Bacillus thuringiensis or B. cereus, such as the binary toxin made up of the VI P1 A and VI P2A proteins (WO 94/21 795); or
• a hybrid insecticidal protein comprising parts from different secreted proteins from Bacillus thuringiensis or Bacillus cereus, such as a hybrid of the proteins in 1 ) above or a hybrid of the proteins in 2) above; or
• a secreted protein from Bacillus thuringiensis or Bacillus cereus which is insecticidal in the presence of a crystal protein from Bacillus thuringiensis, such as the binary toxin made up of VI P3 and Cryl A or Cryl F (US Patent Appl. No. 61 /126083 and 61 /1 9501 9), or the binary toxin made up of the VI P3 protein and the Cry2Aa or Cry2Ab or Cry2Ae proteins (US Patent Appl. No. 1 2/214,022 and EP 0801 0791 .5).
• an insect-resistant transgenic plant also includes any plant comprising a combination of genes encoding the proteins of any one of the above classes 1 to 1 0.
• an insect-resistant plant contains more than one transgene encoding a protein of any one of the above classes 1 to 1 0, to expand the range of target insect species affected when using different proteins directed at different target insect species, or to delay insect resistance development to the plants by using different proteins insecticidal to the same target insect species but having a different mode of action, such as binding to different receptor binding sites in the insect.
• an "insect-resistant transgenic plant”, as used herein, further includes any plant containing at least one transgene comprising a sequence producing upon expression a double-stranded RNA which upon ingestion by a plant insect pest inhibits the growth of this insect pest, as described e.g. in WO 2007/080126, WO 2006/129204, WO 2007/074405, WO 2007/080127 and WO 2007/035650.
• Plants or plant cultivars obtained by plant biotechnology methods such as genetic engineering) which may also be treated according to the invention are tolerant to abiotic stresses. Such plants can be obtained by genetic transformation, or by selection of plants containing a mutation imparting such stress resistance.
• Particularly useful stress tolerance plants include:
• plants which contain a transgene capable of reducing the expression and/or the activity of poly(ADP-ribose) polymerase (PARP) gene in the plant cells or plants as described in WO 00/04173, WO/2006/045633, EP 04077984.5, or EP 06009836.5.
• PARP poly(ADP-ribose) polymerase
• plants which contain a stress tolerance enhancing transgene coding for a plant-functional enzyme of the nicotineamide adenine dinucleotide salvage synthesis pathway including nicotinamidase, nicotinate phosphoribosyltransferase, nicotinic acid mononucleotide adenyl transferase, nicotinamide adenine dinucleotide synthetase or nicotine amide phosphorybosyltransferase as described e.g. in EP 04077624.7, WO 2006/133827, PCT/EP07/002433, EP 1 999263, or WO 2007/1 07326.
• Plants or plant cultivars obtained by plant biotechnology methods such as genetic engineering which may also be treated according to the invention show altered quantity, quality and/or storage-stability of the harvested product and/or altered properties of specific ingredients of the harvested product such as :
• transgenic plants which synthesize a modified starch, which in its physical-chemical characteristics, in particular the amylose content or the amylose/amylopectin ratio, the degree of branching, the average chain length, the side chain distribution, the viscosity behaviour, the gelling strength, the starch grain size and/or the starch grain morphology, is changed in comparison with the synthesised starch in wild type plant cells or plants, so that this is better suited for special applications.
• a modified starch which in its physical-chemical characteristics, in particular the amylose content or the amylose/amylopectin ratio, the degree of branching, the average chain length, the side chain distribution, the viscosity behaviour, the gelling strength, the starch grain size and/or the starch grain morphology, is changed in comparison with the synthesised starch in wild type plant cells or plants, so that this is better suited for special applications.
• Said transgenic plants synthesizing a modified starch are disclosed, for example, in EP 0571427, WO 95/04826, EP 071 9338, WO 96/15248, WO 96/1 9581 , WO 96/27674, WO 97/1 1 1 88, WO 97/26362, WO 97/32985, WO 97/42328, WO 97/44472, WO 97/45545, WO 98/27212, WO 98/40503, W099/58688, WO 99/58690, WO 99/58654, WO 00/081 84, WO 00/081 85, WO 00/081 75, WO 00/28052, WO 00/77229, WO 01 /12782, WO 01 /12826, WO 02/1 01 059, WO 03/071860, WO 2004/056999, WO 2005/030942, WO 2005/030941 , WO
• Examples are plants producing polyfructose, especially of the inulin and levan-type, as disclosed in EP 0663956, WO 96/01904, WO 96/21023, WO 98/39460, and WO 99/24593, plants producing alpha- 1 ,4-glucans as disclosed in WO 95/31553, US 2002031 826, US 6,284,479, US 5,712, 1 07, WO 97/47806, WO 97/47807, WO 97/47808 and WO 00/14249, plants producing alpha-1 ,6 branched alpha-1 ,4-glucans, as disclosed in WO 00/73422, plants producing alternan, as disclosed in e.g. WO 00/47727, WO 00/73422, EP 06077301 .7, US 5,908,975 and EP 0728213,
• transgenic plants which produce hyaluronan, as for example disclosed in WO 2006/032538, WO 2007/039314, WO 2007/039315, WO 2007/03931 6, JP 2006304779, and WO 2005/012529.
• transgenic plants or hybrid plants such as onions with characteristics such as 'high soluble solids content', low pungency' (LP) and/or long storage' (LS), as described in US Patent Appl. No. 12/020,360 and 61 /054,026.
• Plants or plant cultivars which may also be treated according to the invention are plants, such as cotton plants, with altered fiber characteristics.
• plants can be obtained by genetic transformation, or by selection of plants contain a mutation imparting such altered fiber characteristics and include:
• Plants such as cotton plants, having fibers with altered reactivity, e.g. through the expression of N-acetylglucosaminetransferase gene including nodC and chitin synthase genes as described in WO 2006/136351 W01 1 /089021 , WO2012074868
• Plants or plant cultivars which may also be treated according to the invention are plants, such as oilseed rape or related Brassica plants, with altered oil profile characteristics.
• Such plants can be obtained by genetic transformation, or by selection of plants contain a mutation imparting such altered oil profile characteristics and include: a) Plants, such as oilseed rape plants, producing oil having a high oleic acid content as described e.g.
• Plants or plant cultivars which may also be treated according to the invention are plants, such as oilseed rape or related Brassica plants, with altered seed shattering characteristics.
• Such plants can be obtained by genetic transformation, or by selection of plants contain a mutation imparting such altered seed shattering characteristics and include plants such as oilseed rape plants with delayed or reduced seed shattering as described in US Patent Appl. No. 61 /135,230, WO09/068313, W01 0/006732 and WO2012090499.
• Plants or plant cultivars which may also be treated according to the invention are plants, such as Tobacco plants, with altered post-translational protein modification patterns, for example as described in WO 1 0/12181 8 and WO 1 0/145846
• Particularly useful transgenic plants which may be treated according to the invention are plants containing transformation events, or combination of transformation events, that are the subject of petitions for non-regulated status, in the United States of America, to the Animal and Plant Health Inspection Service (APHIS) of the United States Department of Agriculture (USDA) whether such petitions are granted or are still pending.
• APH IS 4700 River Road Riverdale, MD 20737, USA
• URL http://www. aphis. usda.gov/brs/not_reg. html On the filing date of this application the petitions for nonregulated status that were pending with APHIS or granted by APHIS were those which contains the following information:
• Petition the identification number of the petition.
• Technical descriptions of the transformation events can be found in the individual petition documents which are obtainable from APHIS, for example on the APHIS website, by reference to this petition number. These descriptions are herein incorporated by reference.
• Extension of Petition reference to a previous petition for which an extension is requested.
• Institution the name of the entity submitting the petition.
• Transgenic phenotype the trait conferred to the plants by the transformation event. Transformation event or line : the name of the event or events (sometimes also designated as lines or lines) for which nonregulated status is requested.
• APH IS documents various documents published by APHIS in relation to the Petition and which can be requested with APH IS.
• Particularly useful transgenic plants which may be treated according to the invention are plants containing transformation events, or a combination of transformation events, and that are listed for example in the databases for various national or regional regulatory agencies including Event 1 143- 14A (cotton, insect control, not deposited, described in WO2006/128569); Event 1 143-51 B (cotton, insect control, not deposited, described in WO2006/128570); Event 1445 (cotton, herbicide tolerance, not deposited, described in US2002120964 or WO2002/034946); Event 17053 (rice, herbicide tolerance, deposited as PTA-9843, described in WO201 0/1 1 7737); Event 1 7314 (rice, herbicide tolerance, deposited as PTA-9844, described in WO201 0/1 1 7735); Event 281 -24-236 (cotton, insect control - herbicide tolerance, deposited as PTA-6233, described in WO2005/103266 or US200521 6969); Event 3006-21 0-23 (cotton, insect control -
• Event CE43-67B (cotton, insect control, deposited as DSM ACC2724, described in US200921 7423 or WO2006/128573) ; Event CE44-69D (cotton, insect control, not deposited, described in US201 00024077) ; Event CE44-69D (cotton, insect control, not deposited, described in WO2006/128571 ); Event CE46-02A (cotton, insect control, not deposited, described in WO2006/128572) ; Event COT102 (cotton, insect control, not deposited, described in US2006130175 or WO2004039986); Event COT202 (cotton, insect control, not deposited, described in US2007067868 or WO2005054479); Event COT203 (cotton, insect control, not deposited, described in WO2005/054480); Event DAS40278 (corn, herbicide tolerance, deposited as ATCC PTA- 1 0244, described in WO201 1 /02
• PTA-1 1 028, WO2012/033794A2 event MON-87712-4 (soybean, quality trait, ATCC Accession N °. PTA-1 0296, WO2012/051 1 99A2), event DAS-44406-6 (soybean, stacked herbicide tolerance, ATCC Accession N °. PTA-1 1336, WO2012/075426A1 ), event DAS-14536-7 (soybean, stacked herbicide tolerance, ATCC Accession N °. PTA-1 1335, WO2012/075429A1 ), event SYN-000H2-5 (soybean, herbicide tolerance, ATCC Accession N °.
• the composition according to the invention can also be used against fungal diseases liable to grow on or inside timber.
• the term "timber" means all types of species of wood and all types of working of this wood intended for construction, for example solid wood, high-density wood, laminated wood and plywood.
• the method for treating timber according to the invention mainly consists in contacting one or more compounds according to the invention or a composition according to the invention; this includes for example direct application, spraying, dipping, injection or any other suitable means.
• diseases of plants or crops that can be controlled by the method according to the invention mention can be made of :
• Powdery mildew diseases such as :
• Blumeria diseases caused for example by Blumeria graminis ;
• Podosphaera diseases caused for example by Podosphaera leucotricha ;
• Sphaerotheca diseases caused for example by Sphaerotheca fuliginea ;
• Uncinula diseases caused for example by Uncinula necator ;
• Rust diseases such as :
• Gymnosporangium diseases caused for example by Gymnosporangium sabinae ;
• Hemileia diseases caused for example by Hemileia vastatrix ;
• Phakopsora diseases caused for example by Phakopsora pachyrhizi or Phakopsora meibomiae ;
• Puccinia diseases caused for example by Puccinia recondita ;
• Uromyces diseases caused for example by Uromyces appendiculatus ;
• Oomycete diseases such as :
• Bremia diseases caused for example by Bremia lactucae ;
• Peronospora diseases caused for example by Peronospora pisi or P. brassicae ;
• Phytophthora diseases caused for example by Phytophthora infestans ;
• Plasmopara diseases caused for example by P ⁇ asmopara viticola ;
• Pseudoperonospora diseases caused for example by Pseudoperonospora humuli or
• Pythium diseases caused for example by Pythium ultimum ;
• Leafspot, leaf blotch and leaf blight diseases such as :
• Alternaria diseases caused for example by Alternaria solani ;
• Cercospora diseases caused for example by Cercospora beticola ;
• Cladiosporum diseases caused for example by Cladiosporium cucumerinum ;
• Cochliobolus diseases caused for example by Cochliobolus sativus ;
• Colletotrichum diseases caused for example by Colletotrichum lindemuthanium ;
• Cycloconium diseases caused for example by Cycloconium oleaginum ;
• Diaporthe diseases caused for example by Diaporthe citri ;
• Elsinoe diseases caused for example by Elsinoe fawcettii ;
• Gloeosporium diseases caused for example by Gloeosporium laeticolor ;
• Glomerella diseases caused for example by Glomerella cingulata ;
• Guignardia diseases caused for example by Guignardia bidwelli ;
• Leptosphaeria diseases caused for example by Leptosphaeria maculans ; Leptosphaeria nodorum ; Magnaporthe diseases, caused for example by Magnaporthe grisea ;
• Mycosphaerella diseases caused for example by Mycosphaerella graminicola ; Mycosphaerella arachidicola ; Mycosphaerella fijiensis ;
• Phaeosphaeria diseases caused for example by Phaeosphaeria nodorum ;
• Pyrenophora diseases caused for example by Pyrenophora teres ;
• Ramularia diseases caused for example by Ramularia collo-cygni ;
• Rhynchosporium diseases caused for example by Rhynchosporium secalis ;
• Septoria diseases caused for example by Septoria apii or Septoria lycopercisi ;
• Typhula diseases caused for example by Typhula incarnata ;
• Venturia diseases caused for example by Venturia inaequalis ;
• Root and stem diseases such as :
• Corticium diseases caused for example by Corticium graminearum ;
• Fusarium diseases caused for example by Fusarium oxysporum ;
• Gaeumannomyces diseases caused for example by Gaeumannomyces graminis ;
• Rhizoctonia diseases caused for example by Rhizoctonia solani ;
• Tapesia diseases caused for example by Tapesia acuformis ;
• Thielaviopsis diseases caused for example by Thielaviopsis basicola ;
• Ear and panicle diseases such as :
• Alternaria diseases caused for example by Alternaria spp. ;
• Aspergillus diseases caused for example by Aspergillus flavus ;
• Cladosporium diseases caused for example by Cladosporium spp. ;
• Claviceps diseases caused for example by Claviceps purpurea ;
• Fusarium diseases caused for example by Fusarium culmorum ;
• Gibberella diseases caused for example by Gibberella zeae ;
• Monographella diseases caused for example by Monographella nivalis ;
• Smut and bunt diseases such as :
• Sphacelotheca diseases caused for example by Sphacelotheca reiliana ;
• Tilletia diseases caused for example by Tilletia caries ;
• Urocystis diseases caused for example by Urocystis occulta ;
• Ustilago diseases caused for example by Ustilago nuda ;
• Aspergillus diseases caused for example by Aspergillus flavus ;
• Botrytis diseases caused for example by Botrytis cinerea ;
• Penicillium diseases caused for example by Penicillium expansum ;
• Sclerotinia diseases caused for example by Sclerotinia sclerotiorum ;
• Verticilium diseases caused for example by Verticilium alboatrum ;
• Seed and soilborne decay, mould, wilt, rot and damping-off diseases Seed and soilborne decay, mould, wilt, rot and damping-off diseases :
• Aphanomyces diseases caused for example by Aphanomyces euteiches
• Ascochyta diseases caused for example by Ascochyta lentis
• Cladosporium diseases caused for example by Cladosporium herbarum
• Cochliobolus diseases caused for example by Cochliobolus sativus
• Colletotrichum diseases caused for example by Colletotrichum coccodes
• Fusarium diseases caused for example by Fusarium culmorum
• Gibberella diseases caused for example by Gibberella zeae
• Macrophomina diseases caused for example by Macrophomina phaseolina
• Monographella diseases caused for example by Monographella nivalis
• Penicillium diseases caused for example by Penicillium expansum Phoma diseases, caused for example by Phoma lingam
• Phomopsis diseases caused for example by Phomopsis sojae
• Phytophthora diseases caused for example by Phytophthora cactorum
• Pyrenophora diseases caused for example by Pyrenophora graminea
• Pyricularia diseases caused for example by Pyricularia oryzae
• Pythium diseases caused for example by Pythium ultimum
• Rhizoctonia diseases caused for example by Rhizoctonia solani;
• Rhizopus diseases caused for example by Rhizopus oryzae
• Sclerotium diseases caused for example by Sclerotium rolfsii;
• Septoria diseases caused for example by Septoria nodorum
• Typhula diseases caused for example by Typhula incarnata
• Verticillium diseases caused for example by Verticillium dahliae ;
• Canker, broom and dieback diseases such as :
• Nectria diseases caused for example by Nectria galligena ;
• Blight diseases such as :
• Monilinia diseases caused for example by Monilinia laxa ;
• Leaf blister or leaf curl diseases such as :
• Taphrina diseases caused for example by Taphrina deformans ;
• Esca diseases caused for example by Phaemoniella clamydospora ;
• Eutypa dyeback caused for example by Eutypa lata ;
• Botrytis diseases caused for example by Botrytis cinerea ;
• Rhizoctonia diseases caused for example by Rhizoctonia solani
• Helminthosporium diseases caused for example by Helminthosporium solani.
• the compounds according to the invention can also be used for the preparation of composition useful to curatively or preventively treat human or animal fungal diseases such as, for example, mycoses, dermatoses, trichophyton diseases and candidiases or diseases caused by Aspergillus spp., for example Aspergillus fumigatus.
• fungal diseases such as, for example, mycoses, dermatoses, trichophyton diseases and candidiases or diseases caused by Aspergillus spp., for example Aspergillus fumigatus.
• 1 H-NMR data of selected examples are written in form of 1 H-NMR-peak lists. To each signal peak are listed the ⁇ -value in ppm and the signal intensity in round brackets. Between the ⁇ - value - signal intensity pairs are semicolons as delimiters.
• Example 10 Solvent: DMSO, Spectrometer: 400.13 MHz
• Example 12 Solvent: DMSO, Spectrometer: 400.13 MHz
• Example 15 Solvent: DMSO, Spectrometer: 400.13 MHz
• Example 26 Solvent: DMSO, Spectrometer: 400.13 MHz
• Example 30 Solvent: DMSO, Spectrometer: 400.13 MHz
• Example 34 Solvent: DMSO, Spectrometer: 400.13 MHz 11.4902 (0.52); 7.4340 (0.48); 7.4132 (0.98); 7.3947 (0.44); 7.3928 (0.50); 7.2187 (1.73);
• Example 36 Solvent: DMSO, Spectrometer: 400.13 MHz
• Example 40 Solvent: DMSO, Spectrometer: 399.95 MHz
• Example 48 Solvent: DMSO, Spectrometer: 399.95 MHz
• Example 60 Solvent: DMSO, Spectrometer: 399.95 MHz
• Example 65 Solvent: DMSO, Spectrometer: 399.95 MHz
• Example 70 Solvent: DMSO, Spectrometer: 399.95 MHz
• Example 79 Solvent: DMSO, Spectrometer: 399.95 MHz 11.7410 (1.65); 7.9531 (0.84); 7.6582 (2.77); 7.6543 (1.39); 7.6460 (0.89); 7.6408 (3.63);
• Example 80 Solvent: DMSO, Spectrometer: 399.95 MHz
• Example 84 Solvent: DMSO, Spectrometer: 400.13 MHz 12.4305 (3.56); 7.4281 (1.22); 7.4089 (2.60); 7.3896 (1.72); 7.3185 (7.53); 7.3006 (5.10);
• Example 100 Solvent: DMSO, Spectrometer: 499.93 MHz
• Intensity of sharp signals correlates with the height of the signals in a printed example of a NMR spectrum in cm and shows the real relations of signal intensities. From broad signals several peaks or the middle of the signal and their relative intensity in comparison to the most intensive signal in the spectrum can be shown.
• tetramethylsilane For calibrating chemical shift for 1 H spectra, we use tetramethylsilane and/or the chemical shift of the solvent used, especially in the case of spectra measured in DMSO. Therefore in NM R peak lists, tetramethylsilane peak can occur but not necessarily.
• the 1 H-NMR peak lists are similar to classical 1 H-NMR prints and contain therefore usually all peaks, which are listed at classical NMR-interpretation.
• peaks of stereoisomers of the target compounds and/or peaks of impurities have usually on average a lower intensity than the peaks of target compounds (for example with a purity >90%).
• Such stereoisomers and/or impurities can be typical for the specific preparation process. Therefore their peaks can help to recognize the reproduction of our preparation process via "side-products-fingerprints".
• An expert who calculates the peaks of the target compounds with known methods (MestreC, ACD-simulation, but also with empirically evaluated expectation values) can isolate the peaks of the target compounds as needed optionally using additional intensity filters. This isolation would be similar to relevant peak picking at classical 1 H-NM R interpretation.
• 1 H-NM R data of selected examples are written in form of 1 H-NMR-peak lists. To each signal peak are listed the ⁇ -value in ppm and the signal intensity in round brackets. Between the ⁇ - value - signal intensity pairs are semicolons as delimiters.
• the peak list of an example has therefore the form: ⁇ (intensity!); 62 (intensity 2 ); ; ⁇ , (intensity,); ; ⁇ ⁇ (intensity,,)
• Example V-2 Solvent: DMSO, Spectrometer: 250.13 MHz
• Example V-3 Solvent: DMSO, Spectrometer: 300.16 MHz
• Example V-4 Solvent: DMSO, Spectrometer: 400.13 MHz
• Intensity of sharp signals correlates with the height of the signals in a printed example of a NM R spectrum in cm and shows the real relations of signal intensities. From broad signals several peaks or the middle of the signal and their relative intensity in comparison to the most intensive signal in the spectrum can be shown.
• tetramethylsilane For calibrating chemical shift for 1 H spectra, we use tetramethylsilane and/or the chemical shift of the solvent used, especially in the case of spectra measured in DMSO. Therefore in NM R peak lists, tetramethylsilane peak can occur but not necessarily.
• the 1 H-NMR peak lists are similar to classical 1 H-NMR prints and contain therefore usually all peaks, which are listed at classical NMR-interpretation.
• peaks of stereoisomers of the target compounds and/or peaks of impurities have usually on average a lower intensity than the peaks of target compounds (for example with a purity >90%).
• Such stereoisomers and/or impurities can be typical for the specific preparation process. Therefore their peaks can help to recognize the reproduction of our preparation process via "side-products-fingerprints".
• An expert who calculates the peaks of the target compounds with known methods (MestreC, ACD-simulation, but also with empirically evaluated expectation values) can isolate the peaks of the target compounds as needed optionally using additional intensity filters. This isolation would be similar to relevant peak picking at classical 1 H-NM R interpretation.
• Example A In vivo preventive test on Phytophthora infestans (tomato late blight)
• the active ingredients tested are prepared by homogenization in a mixture of acetone/tween/DMSO and then diluted with water to obtain the desired active material concentration.
• Tomato plants ("Rentita” variety), sown in started cups on a 50/50 peat soil-pozzolana substrate and grown at 26 ⁇ , are treated at the Z12 leaf stage by spraying with the active ingredient prepared as described above. Plants, used as controls, are treated with the mixture of acetone/tween/DMSO/water not containing the active material.
• the plants are contaminated by spraying the leaves with an aqueous suspension of Phytophthora infestans spores (20 000 spores per ml).
• the spores are collected from infected plants.
• the contaminated tomato plants are incubated at 1 6-18 °C and at 1 00% relative humidity.
• Example B In vivo preventive test on Alternana brassicae (leaf spot on radish)
• the active ingredients tested are prepared by homogenization in a mixture of acetone/tween/DMSO, and then diluted with water to obtain the desired active material concentration.
• Radish plants ("Pernod Clair” variety), sown in starter cups on a 50/50 peat soil-pozzolana substrate and grown at 17 ⁇ , are treated at the cotyledon stage by spraying with the active ingredient prepared as described above. Plants, used as controls, are treated with the mixture of acetone/tween/DMSO/water not containing the active material.
• the plants are contaminated by spraying the cotyledons with an aqueous suspension of Alternana brassicae spores (50 000 spores per ml).
• the spores are collected from a 15-day-old culture.
• the contaminated radish plants are incubated at 20°C and at 100% relative humidity. Grading (% of efficacy) is carried out 6 days after the contamination, in comparison with the control plants.
• Example C In vivo preventive test on Botrytis cinerea (grey mould)
• the active ingredients tested are prepared by homogenization in a mixture of acetone/tween/DMSO and then diluted with water to obtain the desired active material concentration.
• Gherkin plants ("Vert petit de Paris” variety), sown in starter cups on a 50/50 peat soil-pozzolana substrate and grown at 24°C, are treated at the Z1 1 cotyledon stage by spraying with the active ingredient prepared as described above. Plants, used as controls, are treated with the mixture of acetone/tween/DMSO/water not containing the active material.
• the plants are contaminated by spraying the cotyledons with an aqueous suspension of cryopreserved Botrytis cinerea spores (50 000 spores per ml).
• the spores are suspended in a nutrient solution composed of 1 0 g/L of PDB, 50 g/L of D-Fructose, 2 g/L of NH4NO3 and 1 g/L of KH2PO4.
• the contaminated gherkin plants are incubated at 1 7°C and at 90% relative humidity.
• Example D in vivo preventive test on Sphaerotheca fuliginea (powdery mildew on cucurbits)
• the active ingredients tested are prepared by homogenization in a mixture of acetone/tween/DMSO and then diluted with water to obtain the desired active material concentration.
• Gherkin plants ("Vert petit de Paris” variety), sown in starter cups on a 50/50 peat soil- pozzolana substrate and grown at 24 °C, are treated at the Z1 1 cotyledon stage by spraying with the active ingredient prepared as described above. Plants, used as controls, are treated with the mixture of acetone/tween/DMSO/water not containing the active material.
• the plants are contaminated by spraying the cotyledons with an aqueous suspension of Sphaerotheca fuliginea spores (1 00 000 spores per ml).
• the spores are collected from infected plants.
• the contaminated gherkin plants are incubated at about 20 °C and at 70- 80% relative humidity.
• Example E In vivo preventive test on Pyrenophora teres (net blotch on barley)
• the active ingredients tested are prepared by homogenization in a mixture of acetone/tween/DMSO, and then diluted with water to obtain the desired active material concentration.
• Barley plants (“Plaisant” variety), sown in starter cups on a 50/50 peat soil-pozzolana substrate and grown at 22 °C, are treated at the 1 -leaf stage (10 cm height) by spraying with the active ingredient prepared as described above. Plants, used as controls, are treated with the mixture of acetone/tween/DMSO/water not containing the active material. After 24 hours, the plants are contaminated by spraying the leaves with an aqueous suspension of Pyrenophora teres spores (12 000 spores per ml). The spores are collected from a 12-day- old culture. The contaminated barley plants are incubated for 48 hours at 20 °C and at 1 00% relative humidity, and then for 12 days at 20 ⁇ at 70-80% relative humidity.
• Example F In vivo preventive test on Puccinia recondita (brown rust on wheat)
• the active ingredients tested are prepared by homogenization in a mixture of acetone/tween/DMSO, and then diluted with water to obtain the desired active material concentration.
• Wheat plants (“Scipion” variety), sown in starter cups on a 50/50 peat soil-pozzolana substrate and grown at 22°C, are treated at the 1 -leaf stage (10 cm height) by spraying with the active ingredient prepared as described above. Plants, used as controls, are treated with the mixture of acetone/tween/DMSO/water not containing the active material.
• the plants are contaminated by spraying the leaves with an aqueous suspension of Puccinia recondita spores (1 00 000 spores per ml).
• the spores are collected from an infected plant and are suspended in water containing 2.5 ml/l of Tween 80 at 10%.
• the contaminated wheat plants are incubated for 24 hours at 20 °C and at 1 00% relative humidity, and then for 1 0 days at 20°C and at 70-80% relative humidity.
• Example G In vivo preventive test on Septoria tritici (leaf spot on wheat)
• the active ingredients tested are prepared by homogenization in a mixture of acetone/tween/DMSO, and then diluted with water to obtain the desired active material concentration.
• Wheat plants (“Scipion” variety), sown in starter cups on a 50/50 peat soil-pozzolana substrate and grown at 22 °C, are treated at the 1 -leaf stage (10 cm height) by spraying with the active ingredient prepared as described above. Plants, used as controls, are treated with the mixture of acetone/tween/DMSO/water not containing the active material.
• the plants are contaminated by spraying the leaves with an aqueous suspension of cryopreserved Septoria tritici spores (500 000 spores per ml).
• the contaminated wheat plants are incubated for 72 hours at ⁇ 8 °C and at 1 00% relative humidity, and then for 21 days at 90% relative humidity.
• Example H In vivo preventive test on Phytophthora test (tomato)
• Emulsifier 1 part by weight of alkylaryl polyglycol ether To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.
• the test is evaluated 7 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.
• Example I In vivo preventive test on Plasmopara viticola (grapevines)
• Emulsifier 1 part by weight of alkylaryl polyglycol ether
• a suitable preparation of active compound 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.
• young plants are sprayed with the preparation of active compound at the stated rate of application. After the spray coating has dried on, the plants are inoculated with an aqueous spore suspension of Plasmopara viticola and then remain for 1 day in an incubation cabinet at approximately 20 °C and a relative atmospheric humidity of 1 00%. The plant is subsequently placed for 4 days in a greenhouse at approximately 21 °C and a relative atmospheric humidity of approximately 90%. The plants are then misted and placed for 1 day in an incubation cabinet.
• the test is evaluated 6 days after the inoculation. 0% means an efficacy which corresponds to that of the untreated control, while an efficacy of 100% means that no disease is observed.
• Step 2 To a solution of (2Z)- ⁇ [(2-amino-1 ,3-thiazol-4-yl)methoxy]imino ⁇ (phenyl)acetonitrile (1 0.30 g, 39.87 mmol, 1 eq.) and cesium carbonate (1 1 .02 g, 79.75 mmol, 2.0 eq) in 2-propanol/water (150ml/40ml), was added N-methylhydroxylamine hydrochloride (6.66 g, 79.75 mmol, 2 eq.). The reaction was heated under stirring to 85 °C for 2 h and the solvent was evaporated to 3/4 th . The residue was extracted with EtOAc and washed with water.
• Step 3 To a solution of (2Z)-2- ⁇ [(2-amino-1 ,3-thiazol-4-yl)methoxy]imino ⁇ -N-hydroxy-N-methyl-2-(3- methoxyphenylethanimidamide (2.16 g, 6.44 mmol, 1 eq.) and triethylamine (0.90 ml, 6.44 mmol, 1 eq) in DMF (80 ml) at 0 °C, was added dropwise 4-fluorophenyl chloroformate (1 .15 g, 6.44 mmol, 1 eq.).
• Step 1
• Step 3 Preparation of 3-[(Z)- ⁇ [(2-bromo-1 ,3-thiazol-4-yl)methoxy]imino ⁇ (phenyl)methyl]-2- methyl-1 ,2,4-oxadiazol-5(2H)-one (compound 99)
• Step 1
• Step 2 To a solution of (2Z)- ⁇ [(2-amino-1 ,3-thiazol-4-yl)methoxy]imino ⁇ (phenyl)acetonitrile (1 g, 3.87 mmol, 1 eq.) in dry dichloromethane (15 ml) at room temperature was added pyridine (0.38 ml, 4.65 mmol, 1 .2 eq). After stirring for 15 min at room temperature 2- phenylethylcarbonochloridate (858 mg, 4.65 mmol, 1 .2 eq) was added and stirring was allowed during 5 h. The reaction was quenched by addition of water and concentrated to dryness.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Engineering & Computer Science (AREA)
• Dentistry (AREA)
• Environmental Sciences (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Plant Pathology (AREA)
• Pest Control & Pesticides (AREA)
• Agronomy & Crop Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Dermatology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Plural Heterocyclic Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Priority Applications (9)

Applications Claiming Priority (4)

Publications (1)

Family

ID=48696361

Family Applications (1)

Country Status (12)

Cited By (5)

Families Citing this family (1)

Citations (281)

Family Cites Families (9)

• 2012
  • 2012-12-19 MX MX2014007988A patent/MX343818B/es active IP Right Grant
  • 2012-12-19 CN CN201280064708.2A patent/CN104039769B/zh not_active Expired - Fee Related
  • 2012-12-19 EP EP12809793.8A patent/EP2797895B1/en not_active Not-in-force
  • 2012-12-19 JP JP2014549422A patent/JP5976837B2/ja not_active Expired - Fee Related
  • 2012-12-19 WO PCT/EP2012/076074 patent/WO2013098146A1/en active Application Filing
  • 2012-12-19 IN IN6122DEN2014 patent/IN2014DN06122A/en unknown
  • 2012-12-19 KR KR1020147021200A patent/KR102028893B1/ko not_active Expired - Fee Related
  • 2012-12-19 BR BR112014015993A patent/BR112014015993A8/pt not_active IP Right Cessation
  • 2012-12-19 US US14/368,764 patent/US9326515B2/en not_active Expired - Fee Related
  • 2012-12-19 TW TW101148523A patent/TWI558701B/zh not_active IP Right Cessation
• 2014
  • 2014-06-26 IL IL233420A patent/IL233420A/en active IP Right Grant
  • 2014-07-15 CO CO14152769A patent/CO7010830A2/es unknown

Patent Citations (332)